BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34262096)

  • 1. HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth.
    Fries CN; Chen JL; Dennis ML; Votaw NL; Eudailey J; Watts BE; Hainline KM; Cain DW; Barfield R; Chan C; Moody MA; Haynes BF; Saunders KO; Permar SR; Fouda GG; Collier JH
    Sci Rep; 2021 Jul; 11(1):14494. PubMed ID: 34262096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
    Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
    J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding.
    Berkower I; Patel C; Ni Y; Virnik K; Xiang Z; Spadaccini A
    Virology; 2008 Aug; 377(2):330-8. PubMed ID: 18519142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An HIV-1 envelope immunogen with W427S mutation in CD4 binding site induced more T follicular helper memory cells and reduced non-specific antibody responses.
    Yu HT; Tian D; Wang JY; Guo CX; Li Y; Wang X; Li D; Zhang FM; Zhuang M; Ling H
    PLoS One; 2014; 9(12):e115047. PubMed ID: 25546013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.
    Pantophlet R; Wilson IA; Burton DR
    J Virol; 2003 May; 77(10):5889-901. PubMed ID: 12719582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
    Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.
    Schiffner T; Pallesen J; Russell RA; Dodd J; de Val N; LaBranche CC; Montefiori D; Tomaras GD; Shen X; Harris SL; Moghaddam AE; Kalyuzhniy O; Sanders RW; McCoy LE; Moore JP; Ward AB; Sattentau QJ
    PLoS Pathog; 2018 May; 14(5):e1006986. PubMed ID: 29746590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK; Pancera M; Phogat S; O'Dell S; McKee K; Guenaga J; Robinson J; Mascola J; Wyatt RT
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
    Grundner C; Li Y; Louder M; Mascola J; Yang X; Sodroski J; Wyatt R
    Virology; 2005 Jan; 331(1):33-46. PubMed ID: 15582651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent Primary Immune Responses Induced by Human Immunodeficiency Virus-1 gp120 and Hepatitis B Surface Antigen Determine Antibody Recall Responses.
    Yuan L; Chen WJ; Wang JY; Li Y; Tian D; Wang MX; Yu HT; Xu YC; Li D; Zhuang M; Ling H
    Virol Sin; 2018 Dec; 33(6):502-514. PubMed ID: 30569292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for germline antibody recognition of HIV-1 immunogens.
    Scharf L; West AP; Sievers SA; Chen C; Jiang S; Gao H; Gray MD; McGuire AT; Scheid JF; Nussenzweig MC; Stamatatos L; Bjorkman PJ
    Elife; 2016 Mar; 5():. PubMed ID: 26997349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.
    Zhan X; Slobod KS; Surman S; Brown SA; Lockey TD; Coleclough C; Doherty PC; Hurwitz JL
    J Virol; 2003 Apr; 77(7):4231-6. PubMed ID: 12634380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
    Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
    J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination.
    Hollister K; Chen Y; Wang S; Wu H; Mondal A; Clegg N; Lu S; Dent A
    Hum Vaccin Immunother; 2014; 10(7):1985-92. PubMed ID: 25424808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.